Luminar Technologies 주식 (NASDAQ: LAZR)

에 대한 최신 뉴스 Luminar Technologies (NASDAQ:LAZR) 주식

Luminar Technologies

Luminar Technologies Inc is an automotive technology company ushering in a new era of vehicle safety and autonomy. It operates its business through the following segments: Autonomy Solutions and Advanced Technologies and Services. The majority of its revenue is generated from the Autonomy Solutions segment, which engages in the design, manufacturing, and sale of LiDAR sensors, catering mainly to the OEMs in the automobile, commercial vehicle, robo-taxi, and adjacent industries. The Advanced Technologies and Services segment provides semiconductors and related components, as well as design, test, and consulting services to the Autonomy Solutions segment and various third-party customers. Geographically, the company derives its key revenue from North America.

Xpeng, Hesai Group, Kohl's, Groupon, And Tesla: Why These 5 Stocks Are On Investors' Radars Today

Equities

News

Markets

BABA

INTC

LAZR

RDDT

TSLA

월요일(17일) 미국 증시는 S&amp;P 500 지수가 0.65% 이상 상승한 5,675.12포인트, 나스닥 종합 지수가 0.3% 상승한 17,808.66포인트를 기록하는 등 눈에 띄는 상승세를 보였다. 주목을 받은 주식은 다음과 같다. 테슬라, 루미나, 레딧, 인텔 및 알리바바

월요일 주목받은 주식: 테슬라, 루미나, 레딧, 인텔 및 알리바바

xr:d:DAFiTj-G91w:2,j:46671859577,t:23050806

Earnings

Pre-Market Outlook

Trading Ideas

SAVE

타이슨 푸드(NYSE:TSN)의 오늘 개장 전 분기 실적을 발표할 예정인데, 벤징가 프로의 데이터에 의하면 월가는 주당 39센트의 이익과 131.6억 달러의 매출을 나타낼 것으로 예상하고 다. 타이슨 푸드는 시간외 거래에서 0.1% 상승한 62.05달러에 거래됐다.

타이슨 푸드, 스피릿 항공 및 월요일에 주목해야 3개 주식

Luminar Technologies, Inc. - Class A Common Stock

Luminar Technologies Inc

SRFM

Surf Air Mobility Shares Halted On Circuit Breaker To The Upside, Stock Now Up 40%

<a href="https://www.bloomberg.com/news/articles/2025-06-25/google-debuts-gemini-ai-coding-tool-in-bid-to-entice-developers">https://www.bloomberg.com/news/articles/2025-06-25/google-debuts-gemini-ai-coding-tool-in-bid-to-entice-developers</a>

General

GOOG

GOOGL

'Google Debuts Gemini AI Coding Tool in Bid to Entice Developers'- Bloomberg

Wells Fargo analyst Michael Blum maintains Cheniere Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNG#NYSE">LNG</a>) with a Overweight and raises the price target from $253 to $267.

Price Target

Analyst Ratings

Wells Fargo Maintains Overweight on Cheniere Energy, Raises Price Target to $267

Wells Fargo analyst Michael Blum maintains Cheniere Energy Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CQP#NYSE">CQP</a>) with a Underweight and raises the price target from $59 to $61.

Wells Fargo Maintains Underweight on Cheniere Energy Partners, Raises Price Target to $61

Urgent.ly Shares Halted On Circuit Breaker To The Upside, Stock Now Up 94.8%

Cantor Fitzgerald analyst Deepak Mathivanan maintains Uber Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) with a Overweight and raises the price target from $96 to $106.

UBER

Cantor Fitzgerald Maintains Overweight on Uber Technologies, Raises Price Target to $106

Wells Fargo analyst Michael Blum maintains Sunrun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) with a Overweight and lowers the price target from $10 to $8.

Wells Fargo Maintains Overweight on Sunrun, Lowers Price Target to $8

Wells Fargo analyst Chris Carey maintains Molson Coors Beverage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>) with a Overweight and lowers the price target from $65 to $58.

Wells Fargo Maintains Overweight on Molson Coors Beverage, Lowers Price Target to $58

Cantor Fitzgerald analyst Deepak Mathivanan reiterates Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) with a Neutral and maintains $171 price target.

Reiteration

Cantor Fitzgerald Reiterates Neutral on Alphabet, Maintains $171 Price Target

Wells Fargo analyst Chris Carey maintains Constellation Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) with a Overweight and lowers the price target from $210 to $196.

Wells Fargo Maintains Overweight on Constellation Brands, Lowers Price Target to $196

Cantor Fitzgerald analyst Deepak Mathivanan maintains DoorDash (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) with a Overweight and raises the price target from $210 to $260.

DASH

Cantor Fitzgerald Maintains Overweight on DoorDash, Raises Price Target to $260

AST SpaceMobile Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) shares are sliding Wednesday morning after the company announced a <a href="https://www.benzinga.com/pressreleases/25/06/b46090721/ast-spacemobile-prices-repurchase-of-convertible-notes-and-registered-direct-offering-of-class-a-c">registered direct offering</a>.
What Happened: AST SpaceMobile announced a series of transactions that will result in the company issuing approximately 1.04 million incremental shares to the underlying shares of its 2032 convertible notes.
The company priced a cash repurchase of $225 million of its 4.25%&nbsp;convertible notes due 2032 pursuant to privately negotiated repurchase transactions with certain holders, and also announced a registered direct offering of 9.45 million shares to holders of the 2032 convertible notes that are participating in the repurchase. 
The transactions are expected to remove $225 million of debt from the company&#8217;s balance sheet and approximately $63.8 million of remaining interest. 
AST SpaceMobile said it has agreed to sell the 9.45 million shares in the direct offering at $53.22 per share. The offering and the repurchase are expected to take place on or about July 1. 
&#8220;We are excited to retire approximately half of our 2032 convertible notes and the underlying shares at a price attractive to our shareholders in a series of innovative transactions. These transactions allow us to substantially reduce our outstanding debt and cash interest obligations,&#8221; said Scott Wisniewski, president of AST SpaceMobile.
AST SpaceMobile had a total of $874.5 million in cash, cash equivalents and restricted cash as of March 31, as well as $462.2 million of long-term debt. 
Scotiabank analyst Andres Coello downgraded AST SpaceMobile from <a href="https://www.benzinga.com/analyst-stock-ratings">Sector Outperform</a> to Sector Perform on Monday with a price target of $45.40. The downgrade comes after the stock more than doubled over the past month. 
ASTS Price Action: <a href="http://benzinga.com/quote/asts">AST SpaceMobile shares</a> were down 2.11% at $52.09 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/space/25/06/46090664/india-may-have-been-to-mars-and-moon-but-an-indian-hasnt-been-in-space-for-41-years-elon-musk-just-changed-that">India May Have Been To Mars And Moon, But An Indian Hasn&#8217;t Been In Space For 41 Years: Elon Musk Just Changed That</a></li>
</ul>
Photo: JLStock/Shutterstock.

Movers

ASTS

AST SpaceMobile Stock Is Falling Wednesday: What's Happening?

Invesco QQQ ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) just flashed <a href="https://www.benzinga.com/topic/golden-cross">a Golden Cross</a>, and it's not just a technical footnote &#8211; it's a bullish billboard.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0625"><img loading="lazy" decoding="async" width="627" height="486" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25082252/Screenshot-2025-06-25-at-12.58.33-PM.png" alt="" class="wp-image-961528" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25082252/Screenshot-2025-06-25-at-12.58.33-PM.png 627w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/25082252/Screenshot-2025-06-25-at-12.58.33-PM-300x233.png 300w" sizes="(max-width: 627px) 100vw, 627px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0625">Chart created using Benzinga Pro</a>
<h2 class="wp-block-heading">Golden Cross Confirms The Breakout</h2>
A Golden Cross occurs when the 50-day simple moving average (SMA) crosses above the 200-day SMA, a widely watched indicator that often signals the start of a longer-term uptrend. And in QQQ's case, that signal is now backed by price strength and a powerful tech-heavy backbone.
Read Also: <a href="https://www.benzinga.com/markets/tech/25/06/46074385/nasdaq-seasonality-summer-record-highs">Nasdaq 100&#8217;s Summer Sweet Spot Is Here &#8211; And It Rarely Disappoints</a>
The ETF, which closed Tuesday at $539.78, is now trading above all key simple moving averages (SMA) &#8211; eight, 20, 50 and 200-day. The eight-day SMA sits at $531.40, the 20-day at $528.09, and the 50-day at $501.48 &#8211; each confirming strong upward momentum. 
Even the MACD (Moving Average Convergence Divergence) sits at 7.87, adding to the bullish case. With an RSI (Relative Strength Index) of 66.09, QQQ isn't yet overbought, but it's clearly heating up.
And the fuel? 
<h2 class="wp-block-heading">Netflix, Meta, Microsoft Lead The Charge</h2>
Among the holdings, Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>), Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) and Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) are up 44.25%, 18.85% and 17.09% YTD &#8211; the top performers among QQQ's top 10 holdings in 2025.
While Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) are dragging, the market-cap heavyweights are still pulling weight &#8211; Meta riding AI monetization, Netflix cashing in on content strategy and ad tiers, and Microsoft powering ahead with cloud and enterprise strength.
The 52-week high of $540.81, set back in February, is now within whispering distance. If that level is cleared, QQQ may start attracting even more momentum chasers.
Investors looking for a growth barometer beyond individual stocks often use QQQ as a sentiment proxy for the Nasdaq 100. With a technical breakout now confirmed and tech bellwethers doing the heavy lifting, the question isn't whether QQQ is rallying &#8211; it's whether you&#8217;re already in.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46079549/tech-stocks-eye-record-highs-crude-drops-to-64-on-iran-israel-truce-whats-driving-markets-tuesday">Tech Stocks Eye Record Highs, Crude Drops To $64 On Iran-Israel Truce: What&#8217;s Driving Markets Tuesday?</a></li>
</ul>
Photo: Shutterstock

Technicals

Tech

AAPL

MSFT

NFLX

Netflix, Meta, Microsoft Power QQQ's Golden Cross – Is The Rally Just Beginning?

Citigroup analyst Daniel Grosslight initiates coverage on Waystar Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WAY#NASDAQ">WAY</a>) with a Buy rating and announces Price Target of $45.

Initiation

Citigroup Initiates Coverage On Waystar Holding with Buy Rating, Announces Price Target of $45

High Roller Technologies ("High Roller" and the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROLR#NYSE">ROLR</a>), operator of award-winning premium online casino brands <a href="https://www.globenewswire.com/Tracker?data=8x8JWEQchVtbz2593OWl5lw-T0r-BbPkTWbhjsnuxDCln3v0CkMEx4cWkJtq2FSlHjr1JvC-jfYgGTiDvrlyUGuqCwHkddQpzHJ9gXLDyhI=">High Roller</a>&nbsp;and&nbsp;<a href="https://www.globenewswire.com/Tracker?data=lhbP1vbufkfCZkKUoAWlSj4VUP1BF5ZrOT8OF8Xh6Xdu-CUK1j46LZgzkvYNiTb524cZoS-t1gDShubCsBxUeA==">Fruta</a>, today announced a partnership with onboarding and identity solutions provider Checkin.com to leverage its ID verification products and services in Ontario.
High Roller has submitted its license application to enter Ontario's regulated online casino market, and subject to licensing and approval, the Company anticipates launching live operations in the market in H2 2025.

ROLR

High Roller Partners With Checkin.com To Leverage ID Verification Products And Services In Ontario

STAAR Surgical Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>), the global leader in phakic IOLs with the EVO family of Implantable Collamer&#xAE; Lenses (EVO ICL&#x2122;) for vision correction, today announced that Deborah Andrews has been appointed Chief Financial Officer, effective June 25, 2025. Ms. Andrews has served as Interim CFO since March 2025, and she previously served as STAAR's CFO from 2007-2013 and 2017-2020.
Separately, STAAR announced the formation of a new committee of its Board of Directors, the Capital Stewardship Committee, which will be chaired by Board member Lilian Y. Zhou. The Board determined to establish this new committee to help guide the Company's financial strategies, including the responsible allocation, management and oversight of capital. Ms. Zhou brings extensive experience in institutional investing and investment banking to chair this new committee. "Capital allocation is a key focus for STAAR given our growth prospects, strong cash flow generation, and opportunities to drive long-term value from our propriety Collamer&#xAE; material," said Ms. Zhou. "STAAR is dedicated to enhancing long-term shareholder returns, and I am excited to work with Steve and Deborah to drive STAAR's financial strategies and help build trust and credibility with investors."

Management

STAA

STAAR Surgical Appoints Deborah Andrews As CFO, Effective June 25, 2025

Citigourp Global Markets 2% Protected Notes Linked To The Djia

TCEHY

From NYSE To Hong Kong: Over 80 Chinese Firms Pull Plug On US Listings Amid Growing Tensions

<a href="https://icecure-medical.com/">IceCure Medical Ltd.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCM#NASDAQ">ICCM</a>) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that its board of directors approved a rights offering (the "Rights Offering") to all holders of record of the Company's ordinary shares as of 5:00 p.m. Eastern Time on July 9, 2025 (the "Record Date"). Under the Rights Offering, each holder of the Company's ordinary shares as of the Record Date will receive one right (the "Subscription Right") for each ordinary share held. Each Subscription Right will entitle the holder to subscribe for 0.1703 of a unit, each comprised of one ordinary share and a warrant to purchase one ordinary share at a subscription price of $1.00 per unit or, in lieu of such unit, one unit, each comprised of one pre-funded warrant to purchase one ordinary share and one warrant to purchase one ordinary share, at a subscription price of $0.9999 per unit. No fractional Subscription Rights are being distributed and no fractional units will be issued upon the exercise of any Subscription Rights in the Rights Offering. Shareholders must exercise Subscription Rights for at least one whole unit to participate in the Rights Offering. The Subscription Rights will expire if they are not exercised by 5:00 p.m., Eastern Time, on July 28, 2025, the expected expiration date of the Rights Offering. The Company may extend the period for exercising the Subscription Rights. Subscription Rights which are not exercised by the expiration date of the Rights Offering will expire and will have no value.
Assuming the Rights Offering is fully subscribed, the Company expects to receive aggregate gross proceeds of $10 million. Each holder of the Company's ordinary shares as of the Record Date may over-subscribe for additional units, which will be issued on a pro rata basis if the Rights Offering is not fully subscribed. Epoch Partner Investments Limited ("Epoch"), the Company's largest shareholder, has committed to participate in the Rights Offering and exercise its Subscription Right in full and any over-subscription privilege to purchase units not subscribed for by other shareholders with an aggregate subscription price of up to $5 million. Li Haixiang, the sole director of Epoch, is a member of the board of directors of the Company. As previously announced by the Company on May 21, 2025, Epoch granted IceCure a $2 million unsecured loan on May 17, 2025 bearing interest of 4.05% (the "Bridge Loan"). The Bridge Loan will be repaid after 12 months or upon the completion of the Rights Offering, whichever is earlier. The Company intends to use the proceeds of the Rights Offering, including proceeds directly raised from Epoch's participation in the Rights Offering, to repay the principal and any accrued interest from the Bridge Loan and for general corporate and working capital purposes.
The expected calendar for the rights offering is as follows:
<ul>
<li>July 8, 2025: Ownership Day – in order to be considered a shareholder of record on July 9, 2025, shares should be acquired by this date</li>
<li>July 9, 2025: Record Date (5:00 p.m. Eastern Time)</li>
<li>July 10, 2025: Distribution Date; Subscription Period Begins</li>
<li>July 28, 2025: Subscription Period Ends 5:00 p.m. Eastern Time</li>
</ul>

Offerings

ICCM

IceCure Medical Launches $10M Rights Offering At $1.00/Unit; Company's Largest Shareholder, Epoch Commits Up To $5M

<ul>
<li>TSLA</li>
<li>CRCL</li>
<li>BULL</li>
<li>AMD</li>
<li>NVDA</li>
<li>HOOD</li>
<li>ASTS</li>
<li>GOOGL</li>
<li>BBAI</li>
<li>AAPL</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

BBAI

BULL

CRCL

HOOD

NVDA

Top 10 Trending Stocks On WallStreetBets As Of June 25, 2025 (Via Swaggy Stocks)

Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) and Kymera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>) on Wednesday entered into an exclusive option and license agreement to accelerate the development and commercialization of a novel molecular glue degrader (MGD) program targeting cyclin-dependent kinase 2 (CDK2), with broad <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">oncology treatment potential</a>.
CDK2-directed MGDs are a new type of drug designed to remove CDK2, a key contributor to tumor growth, rather than just inhibiting its function.
Kymera can receive up to $750 million in total payments, including up to $85 million in upfront and potential <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b46091245/gilead-sciences-and-kymera-therapeutics-enter-into-exclusive-option-and-license-agreement-to-devel" rel="noreferrer noopener">option exercise payments</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45724030/kymera-therapeutics-says-atopic-dermatitis-potential-matches-sanofi-regenerons-blockbuster-dupixent-in-early-biomarker-response" rel="noreferrer noopener">Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron&#8217;s Blockbuster Dupixent In Early Biomarker Response</a>
In addition, Kymera may receive tiered royalties ranging from the high single-digits to the mid-teens on net product sales under the collaboration. Kymera will lead all research activities for the CDK2 program.
If Gilead exercises its option to exclusively license the program, Gilead will have global rights to develop, manufacture, and commercialize all products resulting from the collaboration.
The transaction with Kymera is expected to reduce Gilead&#8217;s GAAP and non-GAAP 2025 EPS by approximately $0.02-$0.03.
The core of this collaboration lies in the innovative approach of MGDs. Unlike traditional inhibitors that merely block the function of disease-driving proteins, MGDs work by selectively eliminating these proteins.
As Flavius Martin, MD, Executive Vice President, Research, Gilead Sciences, stated, this mechanism &#8220;aligns within our oncology scientific framework where we evaluate therapeutic agents that selectively target and kill cancer cells with minimal impact on healthy tissue.&#8221;
Nello Mainolfi, PhD, Founder, President and CEO, Kymera Therapeutics, highlighted that their &#8220;highly specific, orally active, CDK2 molecular glue degraders have demonstrated a compelling preclinical profile.&#8221;
Concurrently, Kymera Therapeutics announced an update on its IRAK4 partnership with Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>).
Sanofi has informed Kymera that KT-485/SAR447971, an oral, highly potent, and selective development candidate targeting IRAK4 for immuno-inflammatory diseases that Kymera has discovered and characterized through preclinical studies, has been selected to advance <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g46091325/kymera-therapeutics-announces-sanofi-irak4-collaboration-update" rel="noreferrer noopener">into clinical studies</a>.
Following preclinical work supporting its development potential, KT-485 is being prioritized for development under the companies&#8217; existing IRAK4 collaboration and is expected to advance into Phase 1 testing next year.
Based on the planned development of KT-485, Sanofi <a target="_blank" href="https://www.benzinga.com/general/biotech/22/12/30076238/kymera-therapeutics-stock-jumps-after-positive-data-from-atopic-dermatitis-trial" rel="noreferrer noopener">will not advance KT-474</a>.
Sanofi was conducting Phase 2 trials for hidradenitis suppurativa and <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/g39675035/kymera-announces-expansion-of-kt-474-sar444656-hs-and-ad-phase-2-studies-following-interim-review-" rel="noreferrer noopener">atopic dermatitis indications</a>.
In conjunction with its plans to advance KT-485, Sanofi also communicated its decision to exercise its participation election right for the IRAK4 target under the companies&#8217; collaboration agreement terms.
Under the agreement, Kymera achieved a $20 million milestone in the second quarter of 2025 related to preclinical activities associated with KT-485.
Kymera can receive up to $975 million of potential clinical, regulatory, and commercial milestones related to KT-485, including an additional milestone upon the start of Phase 1 clinical testing.
Price Action: SNY stock is down 0.76% at $48.05, KYMR stock is down 4.54% at $45, and GILD stock is down 0.28% at $106.90 during the premarket session at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46093513/sam-altman-crushes-openai-microsoft-feud-rumors-hails-really-wonderfully-good-bond-with-satya-nadella" target="_blank" rel="noreferrer noopener">Sam Altman Crushes OpenAI-Microsoft Feud Rumors, Hails &#8216;Really Wonderfully Good&#8217; Bond With Satya Nadella</a></li>
</ul>
Photo by Aunt Spray via Shutterstock

Biotech

Large Cap

Health Care

GILD

KYMR

Gilead Bets On Kymera's CDK2 Molecular Glue Degrader For New Cancer Therapies

Press Releases

Luminar Obtains $200 Million Capital Commitment to Bolster Balance Sheet & Liquidity

Luminar Improves Capital Structure with Repurchase of $50 Million in 2026 Convertible Senior Notes

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Luminar Technologies, Inc. - LAZR

Penny Stocks

LAZR Investors Have Opportunity to Join Luminar Technologies, Inc. Fraud Investigation with the Schall Law Firm

Legal

INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation Of Luminar Technologies, Inc. (NASDAQ: LAZR) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm

American Axle & Manufacturing Holdings, Inc. Common Stock

American Axle & Mfg Hldgs

China Automotive Systems, Inc. - Common Stock

China Automotive Systems

Cooper-Standard Holdings Inc. Common Stock

Cooper-Standard Holdings

ECARX Holdings Inc. - Class A Ordinary shares

ECARX Holdings

Fox Factory Holding

Foresight Autonomous Holdings Ltd. - American Depositary Shares

Foresight Autonomous

Holley

Kandi Technologies Group, Inc. - Ordinary Shares

Kandi Technologies Group

MKDWell Tech

Motorcar Parts of America, Inc. - Common Stock

Motorcar Parts of America

Mingteng International Corporation Inc. - Ordinary Shares

Mingteng International

REE Automotive Ltd. - Class A Ordinary Shares

REE Automotive

Solid Power

Standard Motor Products, Inc. Common Stock

Standard Motor Products

Stoneridge

STRATTEC SECURITY CORPORATION - Common Stock

Strattec Security

Superior Industries Intl

Sypris Solutions

Gentherm

Worksport

XPEL

Goldman Sachs

Craig-Hallum

Rosenblatt

Deutsche Bank

Citigroup

월요일(17일) 미국 증시는 S&amp;P 500 지수가 0.65% 이상 상승한 5,675.12포인트, 나스닥 종합 지수가 0.3% 상승한 17,808.66포인트를 기록하는 등 눈에 띄는 상승세를 보였다. 이러한 상승에도 불구하고 지수는 주간 손실을 기록했으며, 특히 S&amp;P 500 지수는 4주 연속 손실을 나타냈다. 다우존스 지수도 약 354포인트(0.85%) 상승한 41,841.63포인트로 마감했다.
월요일에 소매 투자자와 트레이더들의 주목을 받은 주식은 다음과 같다.
<h3>테슬라 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)</h3>
월요일 테슬라 주가는 4.79% 하락하여 238.01달러에 마감했으며, 장중 최고가는 245.40달러, 최저가는 232.80달러였다. 또한 52주 최고가는 488.54달러, 최저가는 138.80달러다. 투자자들은 스페이스X와 뉴럴링크를 포함한 여러 벤처에 대한 <a href="//in.benzinga.com/news/25/03/44356670/with-doubts-over-musks-tesla-commitment-growing-his-own-words-resurface-he-once-said-he-never-wanted-to-be-ceo-as-it-hurts-his-heart"" target="_blank" rel="noopener">일론 머스크의 주의 분산에 대해 우려</a>하고 있으며 테슬라에 대한 헌신 문제도 다시 부상했다.
<h3>루미나 테크놀로지스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAZR#NASDAQ">LAZR</a>)</h3>
루미나 테크놀로지스는 27.13%의 큰 상승률을 보이며 6.42달러로 마감했다. 이 주식은 장중 최고가 6.50달러, 최저가 5.34달러를 기록했고, 52주 최고가는 34.80달러, 최저가는 4.47달러를 기록했다. 한 유튜버가 루미나의 라이더 시스템과 테슬라의 오토파일럿을 비교하는 동영상을 통해 자율 주행에서 라이더 기술의 잠재력을 보여주며 <a href="https://in.benzinga.com/general/entertainment/25/03/44363063/youtuber-crashes-tesla-into-fake-road-wall-fooling-vehicle-cameras-in-misleading-video" target="_blank" rel="noopener">관심을 불러일으켰다</a>.
<h3>레딧 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>)</h3>
레딧 주가는 2.07% 하락한 125.56달러로 최고가 142달러, 최저가 119.92달러를 기록했다. 52주 최고가는 230.41달러, 최저가는 37.35달러이다. 구글이 레딧과 <a href="https://in.benzinga.com/general/social-media/25/03/44364854/reddit-stocks-late-in-the-day-surge-whats-going-on" target="_blank" rel="noopener">파트너십을 확대하여</a> 구글 제품 전반에 걸쳐 레딧 콘텐츠를 보다 효과적으로 통합하겠다고 발표한 후 주가가 잠시 급등했다.
<h3>인텔 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>)</h3>
인텔의 주가는 6.82% 상승하여 25.69달러로 마감했으며, 장중 최고가 26.15달러, 최저가 24.37달러를 기록했다. 52주 최고가는 45.41달러, 최저가는 18.51달러이다. 인텔의 새로운 CEO인 립-부 탄이 AI 칩 생산과 비용 절감 방안에 초점을 맞춘 회사 운영의 <a href="https://www.benzinga.com/trading-ideas/movers/25/03/44361645/intel-shares-surge-as-new-ceo-plans-major-overhaul-whats-going-on" target="_blank" rel="noopener">대대적인 개편</a>을 계획하고 있다는 보도에 따른 상승세였다.
<h3>알리바바 그룹 홀딩 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>)</h3>
알리바바의 주가는 4.59% 상승한 147.57달러로 장중 최고가 148.43달러, 최저가 140.03달러를 기록했다. 52주 최고가는 148.43달러, 최저가는 68.36달러이다. 월요일의 상승은 중국의 소매판매 수치와 <a href="https://in.benzinga.com/etfs/emerging-market-etfs/25/03/44365756/chinas-ai-surge-fuels-etf-gains-baidu-alibaba-lead-the-way" target="_blank" rel="noopener">기술 부문의 급등</a>으로 인한 긍정적 신호로 시장 심리가 개선된 데 따른 것이었다.
<a href="https://www.benzinga.com/premarket">벤징가 프리마켓 주요 동향 및 뉴스</a>와 함께 오늘의 거래를 준비하세요.
이미지 출처: Shutterstock
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>를 사용하여 생성되었으며, <a href="https://www.benzinga.com/author/shivdeep-dhaliwal">Shivdeep Dhaliwal</a>이 편집했습니다.
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

미국 주식 선물은 현지 시간 월요일 아침 상승하며, 주목받을 수 있는 주식들은 다음과 같다.
<ul>
<li>타이슨 푸드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSN#NYSE">TSN</a>)의 오늘 개장 전 분기 실적을 발표할 예정인데, 벤징가 프로의 데이터에 의하면 월가는 주당 39센트의 이익과 131.6억 달러의 매출을 나타낼 것으로 예상하고 다. 타이슨 푸드는 시간외 거래에서 0.1% 상승한 62.05달러에 거래됐다.</li>
<li>윌리엄스 컴퍼니스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMB#NYSE">WMB</a>)의 월요일 시장 마감 후 분기 실적을 발표할 예정이다. 분석가들은 이번 분기에는 주당 48센트의 이익과 26.9억 달러의 매출을 기록할 것으로 예상했다. 윌리엄스는 시간외 거래에서 0.4% 상승한 38.82달러에 거래됐다.</li>
<li>루미나 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAZR#NASDAQ">LAZR</a>)은 20%의 인력을 축소했으며, 혼조된 분기 실적을 발표했다. 루미나는 시간외 거래에서 1.52달러로 9.5% 하락했다.</li>
</ul>
여러분은 <a href="http://">여기서</a> 개장전 주식 뉴스를 확인하실 수 있습니다.
<ul>
<li>월요일 시장 마감 후 굿이어 타이어 앤드 러버 컴퍼니(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GT#NASDAQ">GT</a>)의 분기 실적은 주당 1센트의 이익과 48.2억 달러의 매출로 예상된다. 굿이어 타이어는 시간외 거래에서 1.5% 하락한 12.06달러에 거래됐다.</li>
<li>분석가들은 스피릿 항공(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAVE#NYSE">SAVE</a>)은 개장 전 분기 발표하는 실적으로 주당 1.45달러의 손실과 12.7억 달러의 매출로 예상하고 있다. 이는 스피릿 항공의 주가는 시간외 거래에서 3.8198달러로 3% 상승했다.</li>
</ul>

Comments

Luminar Technologies

뉴스

에 대한 최신 뉴스 Luminar Technologies (NASDAQ:LAZR) 주식

화요일, 3월 18, 2025

월요일, 5월 06, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌